At the time of writing, Protagonist Therapeutics Inc [PTGX] stock is trading at $53.86, down -1.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTGX shares have gain 0.22% over the last week, with a monthly amount glided 7.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $72. Previously, Goldman started tracking the stock with Neutral rating on December 06, 2024, and set its price target to $47. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $62 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $58 on November 05, 2024. TD Cowen initiated its recommendation with a Buy and recommended $65 as its price target on September 24, 2024. Truist started tracking with a Buy rating for this stock on September 09, 2024, and assigned it a price target of $60. In a note dated October 30, 2023, CapitalOne initiated an Overweight rating and provided a target price of $32 on this stock.
For the past year, the stock price of Protagonist Therapeutics Inc fluctuated between $32.50 and $60.60. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $53.86 at the most recent close of the market. An investor can expect a potential return of 35.54% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
According to Protagonist Therapeutics Inc [NASDAQ:PTGX], the company’s sales were 207.80M for trailing twelve months, which represents an -88.89% plunge. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.09 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.27 points at the first support level, and at 52.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.87, and for the 2nd resistance point, it is at 55.88.
Ratios To Look Out For
It is important to note that Protagonist Therapeutics Inc [NASDAQ:PTGX] has a current ratio of 17.26. On the other hand, the Quick Ratio is 17.26, and the Cash Ratio is 3.98. Considering the valuation of this stock, the price to sales ratio is 16.07, the price to book ratio is 4.84 and price to earnings (TTM) ratio is 70.80.
Transactions by insiders
Recent insider trading involved PATEL DINESH V PH D, President and CEO, that happened on Jul 25 ’25 when 10415.0 shares were sold. President and CEO, PATEL DINESH V PH D completed a deal on Jul 22 ’25 to sell 22065.0 shares. Meanwhile, President and CEO PATEL DINESH V PH D sold 17520.0 shares on Jul 23 ’25.
